ClinicalTrials.gg
TerminatedNCT04746339APOLLOUpdated Aug 25, 2022

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

A Phase 4 interventional study of Apixaban 2.5 MG and Placebo in Covid19 and Thrombosis, sponsored by Brazilian Clinical Research Institute. Terminated at 4 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-25.

Sponsored by Brazilian Clinical Research Institute · Phase 4, Interventional, and Prevention

How we know

Why this study was terminated
Due to the decrease in COVID cases and in the recruitment rate, and DSMB orientation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
411
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Enrollment
85th of 263
411 · median 205
Started
2021
with 102 others
Phase 4
14 of 317
none open now
Registered
173rd of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 85th largest by enrollment of the 263 interventional ones that give a count, is one of 103 that started in 2021, is one of 14 in phase 4, and was the 173rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.

Read the detailed description

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.

Randomization 1:1 - Group 1 will receive Apixaban 2.5mg twice daily vs. matching placebo (Group 2) for 30 days.

Primary Objective: To evaluate the clinical impact of a strategy of oral anticoagulation with apixaban comparing with placebo on the number of days alive and out of the hospital/emergency department (DAOH) through 30 days in outpatients with symptomatic SARS-CoV2 infection and risk factors for thrombosis.

03

Conditions studied

  • Covid19
  • Thrombosis

Keywords

  • SARS-CoV2
  • Anticoagulation
  • Apixaban
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients with symptomatic laboratory-proven diagnosis of COVID-19 (any exam that shows acute infection as positive PCR or IgM in a context of acute symptoms ≤ 10 days) AND
  • Negative pregnancy test for women in child bearing period AND
  • D-dimer level ≥ 2x or
  • C-reactive protein (CRP) ≥ 10 mg/L or
  • At least two of the following risk factors:

    • d-dimer level ≥ULN
    • CRP ≥ULN
    • age ≥65,
    • diabetes,
    • chronic kidney disease stage 3
    • cardiopulmonary disease (for example, peripheral arterial disease, coronary artery disease, heart failure, ),
    • history of PE/DVT,
    • nursing home/SNF resident or severely restricted mobility
    • ≥30 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years-old
  • Patients with indication for full anticoagulation during inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation, mechanical valve prosthesis)
  • \< 50,000 /mm3
  • Use of acetylsalicylic acid > 100 mg per day
  • Use of P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor)
  • Chronic use of NSAIDs
  • to apixaban
  • \< 30 ml/min
  • Pregnancy or breastfeeding
  • Patients to anticoagulation (active bleeding, recent major surgery, blood dyscrasia or prohibitive hemorrhage risk as evaluated by the investigator)
  • A history of hemorrhagic stroke or any intracranial bleeding at any time in the past or current intracranial neoplasm (benign or malignant), cerebral , arteriovenous (AV) malformation, or aneurysm
  • Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) (e.g. protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
411 participants (actual)

Study arms

  • Active comparator
    Apixaban Group

    Drug: Apixaban 2.5 MG

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of days alive and out of hospital or emergency department

    Number of days alive and out of hospital or emergency department through 30 days.

    Time frame: In 30 days

Secondary outcomes

  1. Hospitalization due to bleeding

    Time frame: In 30 days

  2. Hospitalizations for cardiopulmonary causes

    Time frame: In 30 days

  3. All-cause hospitalization

    Time frame: In 30 days

  4. All-cause death

    Time frame: In 30 days

  5. Days free of venous thromboembolism

    Venous thromboembolism (VTE) include deep venous thrombosis and pulmonary embolism.

    Time frame: In 30 days

  6. Major cardiovascular events (MACE)

    Major cardiovascular events (MACE) includes cardiovascular death, myocardial infarction (MI) and stroke.

    Time frame: In 30 days

07

Study locations

4 sites
  • Hospital Maternidade São Vicente de Paulo
    Barbalha, Ceará, Brazil
  • Hospital Israelita Albert Einstein
    São Paulo, SP, Brazil
  • Hospital Universitário São Francisco de Assis
    Bragança Paulista, São Paulo, Brazil
  • Hospital Santa Paula
    São Paulo, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in May 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 9, 2021
StartActual
Mar 4, 2021
Primary completionActual
May 13, 2022
CompletionActual
May 30, 2022
Last update
Aug 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04746339
Lead sponsor
Brazilian Clinical Research Institute
Collaborators
Hospital Israelita Albert Einstein, Hospital do Coracao, Hospital Sirio-Libanes, Hospital Moinhos de Vento, Hospital Alemão Oswaldo Cruz, Beneficência Portuguesa de São Paulo, Brazilian Research In Intensive Care Network
Responsible party
Sponsor
First posted
Feb 9, 2021
Start date
Mar 4, 2021
Primary completion
May 13, 2022
Completion
May 30, 2022
Last update
Aug 25, 2022

Study contacts

Renato D. Lopes, MD, PhD
study chair · BCRI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion